0.3545
price up icon0.97%   0.0057
 
loading
전일 마감가:
$0.3488
열려 있는:
$0.34
하루 거래량:
27,662
Relative Volume:
0.15
시가총액:
$21.75M
수익:
-
순이익/손실:
$-68.80M
주가수익비율:
-0.303
EPS:
-1.17
순현금흐름:
$-59.06M
1주 성능:
+16.62%
1개월 성능:
+4.82%
6개월 성능:
-30.26%
1년 성능:
-71.13%
1일 변동 폭
Value
$0.34
$0.36
1주일 범위
Value
$0.2774
$0.36
52주 변동 폭
Value
$0.257
$1.33

Passage Bio Inc Stock (PASG) Company Profile

Name
명칭
Passage Bio Inc
Name
전화
(267) 866-0312
Name
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Name
직원
60
Name
트위터
@passage_bio
Name
다음 수익 날짜
2025-03-04
Name
최신 SEC 제출 서류
Name
PASG's Discussions on Twitter

PASG을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PASG
Passage Bio Inc
0.35 18.48M 0 -68.80M -59.06M -1.17
Biotechnology icon
ONC
Beigene Ltd Adr
239.26 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
431.20 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.32 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.30 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.50 5.92B 0 -153.72M -103.81M -2.00

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-29 재개 Wedbush Outperform
2024-09-03 개시 Rodman & Renshaw Buy
2022-03-08 다운그레이드 JP Morgan Overweight → Neutral
2022-01-19 다운그레이드 Goldman Buy → Neutral
2021-07-01 개시 Raymond James Outperform
2021-06-15 개시 BTIG Research Buy
2021-03-04 업그레이드 Goldman Neutral → Buy
2021-02-04 개시 Guggenheim Buy
2021-01-25 개시 Wedbush Outperform
2021-01-04 업그레이드 JP Morgan Neutral → Overweight
2020-12-11 개시 Citigroup Neutral
2020-08-14 다운그레이드 JP Morgan Overweight → Neutral
2020-06-25 다운그레이드 Goldman Buy → Neutral
2020-03-25 개시 Chardan Capital Markets Buy
2020-03-24 개시 Cowen Outperform
2020-03-24 개시 Goldman Buy
2020-03-24 개시 JP Morgan Overweight
모두보기

Passage Bio Inc 주식(PASG)의 최신 뉴스

pulisher
May 20, 2025

Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com

May 20, 2025
pulisher
May 20, 2025

GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com

May 20, 2025
pulisher
May 20, 2025

Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG Stock News - GuruFocus

May 20, 2025
pulisher
May 18, 2025

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MSN

May 18, 2025
pulisher
May 18, 2025

Wedbush Issues Pessimistic Estimate for Passage Bio Earnings - Defense World

May 18, 2025
pulisher
May 16, 2025

Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World

May 16, 2025
pulisher
May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025
pulisher
May 14, 2025

Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech

May 14, 2025
pulisher
May 14, 2025

Passage Bio Reports Q1 2025 Financial Results - TipRanks

May 14, 2025
pulisher
May 13, 2025

Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Passage BIO, Inc. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - The Manila Times

May 13, 2025
pulisher
May 11, 2025

Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 08, 2025

2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked - BioSpace

May 08, 2025
pulisher
Apr 30, 2025

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus

Apr 30, 2025
pulisher
Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 11, 2025

Passage Bio (NASDAQ:PASG) vs. Agenus (NASDAQ:AGEN) Critical Contrast - The AM Reporter

Apr 11, 2025
pulisher
Apr 09, 2025

Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025
pulisher
Apr 03, 2025

GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com

Apr 03, 2025
pulisher
Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 - Investing.com

Mar 31, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com

Mar 27, 2025
pulisher
Mar 25, 2025

Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech

Mar 25, 2025
pulisher
Mar 23, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo

Mar 23, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 16, 2025

Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo

Mar 16, 2025
pulisher
Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia

Mar 13, 2025

Passage Bio Inc (PASG) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.2054
price down icon 12.59%
$31.50
price down icon 3.35%
$578.71
price down icon 0.54%
$286.44
price down icon 0.99%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
자본화:     |  볼륨(24시간):